ARCHIVES

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | November 25, 2011

Download PDF Visit The Full Archive

Related Articles

Loeb Named ACS President, Eyre President Elect

November 14, 1986

States Join Suit Alleging Amgen Offered Illegal Kickback To Doctors For Aranesp

November 6, 2009

41 CCOPs Reported For Recompetition

February 23, 1990

Bristol-Lyers Squibb, Axion In Joint Venture To Sell Oncology Drugs to Office-Base Practices

September 3, 1993

In Brief: ACS Massachusetts Div. Offers $1,500 Grants To Improve community Hospital Cancer Care

March 2, 1979

Core Grants Limit Formula Must Wait On Profiles

January 27, 1978